Joshua Rosenblat

Research Synopsis

Dr. Rosenblat’s clinical focus is treatment-resistant unipolar and bipolar depression, with specialized expertise in pharmacological treatments of mood disorders.  His research focus is conducting clinical trials to identify and evaluate novel psychopharmacological interventions for mood disorders that may substantially improve patient outcomes.  Current novel targets of interest include the glutamate system, inflammation and the insulin pathway. He is also interested in targeting specific symptom domains, such as suicidality, cognition, anhedonia and mixed features, that do not respond as well to currently available treatment. Specific research programs currently underway include clinical trials evaluating ketamine, pentoxifylline and psilocybin assisted therapy for bipolar and unipolar depression.